Clobetasol Propionate 0.025%

Introduction Overview

Generic Name

clobetasol propionate 0.025%

Brand Name

Impoyz

Dosage Form

topical cream

Drug Class

Topical steroids

Pharmacokinetics

Absorption:
Clobetasol propionate in Impoyz cream is absorbed through the skin via topical application. The presence of the solubilizer Transcutol enhances the solubility and penetration of clobetasol into psoriatic plaques more effectively than traditional vehicles such as propylene glycol, thereby increasing local drug bioavailability despite a lower concentration (0.025%) than typical formulations (usually 0.05%). Absorption is generally limited to the site of application but can occur systemically especially with prolonged use or occlusive dressings. Systemic absorption can lead to hypothalamic-pituitary-adrenal (HPA) axis suppression. Factors influencing the rate and extent of absorption include the integrity of the skin barrier, the surface area treated, duration of exposure, and use of occlusive dressings which can significantly increase dermal penetration.

Distribution:
Once absorbed, clobetasol propionate demonstrates high affinity for skin tissues with minimal systemic distribution due to its extensive local metabolism and low systemic bioavailability from topical application. The drug preferentially partitions into lipid layers of the stratum corneum and epidermis aided by Transcutol, which also preserves the skin’s lamellar lipid structure better than other vehicle components. Systemically absorbed drug binds to glucocorticoid receptors present intracellularly to exert anti-inflammatory effects. However, plasma concentrations remain very low during recommended topical use, limiting distant tissue exposure but systemic side effects can occur with excessive use.

Metabolism:
Clobetasol propionate undergoes rapid metabolism within the skin and liver primarily via hydrolysis and reduction. Extensive first-pass metabolism occurs if absorbed systemically, involving cytochrome P450 enzymes as well as esterases that convert the propionate ester to inactive metabolites. The metabolic pathway limits systemic activity and toxicity because the active corticosteroid moiety is rapidly converted to inactive compounds once reaching circulation. Metabolites are pharmacologically inactive and excreted predominantly via renal elimination.

Elimination:
Systemically absorbed clobetasol propionate and its metabolites are eliminated primarily through renal excretion. The drug has a relatively short systemic half-life due to rapid hepatic metabolism and clearance. Topical application results in minimal systemic clearance demands given the limited systemic exposure, but prolonged use can lead to accumulation particularly with occlusive dressings or extensive surface area treated. Monitoring for systemic corticosteroid effects is recommended with excessive or prolonged therapy. Overall, elimination kinetics support the use of short-duration applications (generally not to exceed 2 weeks) to minimize systemic toxicity.

Dosage Forms

Available Dosage Forms:
Impoyz is supplied as a topical cream containing clobetasol propionate 0.025%, available in aluminum tubes of 60 grams and 112 grams. This cream base includes Transcutol (diethylene glycol monoethyl ether) as a penetration enhancer. The formulation offers a lower concentration of clobetasol compared to standard 0.05% creams but achieves equivalent efficacy due to enhanced skin penetration.

Dosages for Adults and Adolescents:
Impoyz cream is indicated for adults aged 18 years and older for the treatment of moderate to severe plaque psoriasis. The recommended dosage is to apply a thin layer twice daily to affected areas. The total dose should not exceed 50 grams per week. Treatment duration must not exceed 2 weeks to limit systemic absorption and reduce the risk of adverse events.

Specific Patient Populations:
Use in pediatric patients under 18 years is contraindicated due to higher susceptibility to systemic corticosteroid absorption and adverse effects. Safety in pregnant and breastfeeding women has not been fully established; if used, minimal quantity and shortest duration are advised. Use cautiously in patients with diabetes mellitus due to possible elevation in blood glucose caused by topical corticosteroids. Patients with liver disease or adrenal gland disorders should inform their physicians before use.

Clinical Guidelines:
The cream should not be applied to thin skin, face, scalp, axillae, groin, or skin folds. Occlusive dressings should be avoided unless explicitly directed by a physician. Therapeutic use should cease once clinical control of psoriasis is achieved or at completion of 2 weeks. If no improvement is observed within this period, discontinuation and reassessment are warranted.

Mechanism Of Action

Impoyz cream’s active ingredient, clobetasol propionate, is a super potent corticosteroid with remarkable anti-inflammatory, antipruritic, and vasoconstrictive properties. Its primary molecular mechanism involves binding to intracellular glucocorticoid receptors in skin cells, leading to modulation of gene expression that suppresses the production of pro-inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This blockade reduces vasodilation, edema, and leukocyte infiltration into affected skin areas.

At the cellular level, clobetasol stabilizes lysosomal membranes, decreases capillary permeability, and inhibits the migration of neutrophils and other immune cells into inflamed tissue, which decreases dermal inflammation and scaling. It also suppresses fibroblast activity and collagen synthesis, contributing to its anti-proliferative effects on psoriatic plaques. The antipruritic effect is achieved through both anti-inflammatory action and local neuronal modulation, diminishing skin itch sensation.

The formulation of Impoyz incorporates Transcutol, a penetration enhancer that improves clobetasol’s solubility and facilitates deeper dermal and epidermal absorption specifically targeting thickened psoriatic plaques. This mechanism enables lower steroid concentrations to achieve efficacy comparable to higher potency creams, thereby reducing systemic corticosteroid exposure and related side effects.

Clinically, the potent suppression of inflammatory gene transcription leads to rapid amelioration of psoriasis symptoms such as redness, scaling, and pruritus, typically within days. Comparative studies show clobetasol’s superior efficacy over medium-potency steroids like triamcinolone. However, its high potency necessitates strict usage limitations due to risk of HPA axis suppression and local side effects. Research supports limiting treatment duration to brief courses with close monitoring to balance efficacy and safety.

Pharmacological Actions

Powerful anti-inflammatory action via inhibition of multiple inflammatory pathways in the skin.
Strong vasoconstrictive effects reducing erythema and edema in lesions.
Antipruritic effects alleviating itch associated with plaque psoriasis.
Immunosuppressive effects decreasing local immune cell activation and infiltration.
Stabilization of lysosomal membranes reducing release of inflammatory enzymes.
Inhibition of fibroblast proliferation and collagen synthesis reducing plaque hyperproliferation.
Enhanced dermal penetration due to Transcutol, increasing local bioavailability at lower drug concentrations.
Reduction of pro-inflammatory cytokines and suppression of gene expression involved in psoriasis pathogenesis.
Rapid symptomatic relief of scaling, redness, and pruritus in affected skin areas.
Potential to cause reversible HPA axis suppression when systemically absorbed.
Minimal systemic effects with recommended topical application and short duration of use.
Less disruption of skin lamellar lipid structure compared to propylene glycol-based formulations.
Effective for treatment of moderate to severe plaque psoriasis in adults.

Therapeutic Or Clinical Uses

Topical treatment of moderate to severe plaque psoriasis in adults aged 18 years and older.
Reduction of inflammation and itching associated with psoriatic plaques.
Short-term management of corticosteroid-responsive dermatoses.
Used when high potency topical corticosteroid is required but with reduced steroid concentration.
Alternative to standard 0.05% clobetasol creams with lower risk of systemic absorption.
Off-label use for inflammatory scalp disorders when combined with appropriate vehicles.
Treatment for corticosteroid-responsive skin conditions distinct from facial and intertriginous areas.
Management of localized psoriasis plaques unresponsive to lower potency steroids.
Adjunctive therapy preceding or following systemic psoriasis treatments to control localized lesions.
Utility in adults with skin conditions not adequately controlled by medium potency steroids.
Effective option for patients requiring potent anti-inflammatory topical steroid with improved safety profile.
Treatment limited to 2 weeks to minimize adverse effects.
Not recommended for use on thin skin or certain sensitive areas.
Used under medical supervision with strict adherence to dosing guidelines.

Side Or Adverse Effects

Discoloration or hypopigmentation of the skin at the site of application.
Local skin irritation including burning, itching, swelling, or redness.
Dryness, cracking, or thinning of the treated skin due to corticosteroid-induced atrophy.
Allergic contact dermatitis and rash including hives.
Development of acneiform eruptions or folliculitis evidenced by redness and crusting around hair follicles.
Stretch marks (striae) resulting from prolonged or excessive use.
Spider veins (telangiectasia) on treated skin areas.
Temporary hair loss occurring rarely at the application site.
Increased risk of secondary skin infections requiring antimicrobial therapy.
Potential reversible suppression of the hypothalamic-pituitary-adrenal (HPA) axis presenting with systemic corticosteroid insufficiency.
Symptoms of systemic absorption including facial and shoulder weight gain, mood changes, tiredness, menstrual irregularities, and sexual dysfunction.
Contraindicated for use on thin skin areas; misuse can aggravate adverse effects.
Occlusive dressings increase risk of systemic side effects and skin damage.
Rare occurrence of corticosteroid-induced hyperglycemia and glucosuria.
Not intended for use exceeding 2 weeks to limit risk of systemic toxicity.

Precautions

Do not use Impoyz cream for longer than 2 weeks to prevent systemic corticosteroid side effects.
Avoid application to thin skin areas, face, scalp, armpits, groin, or skin folds.
Do not apply occlusive dressings unless explicitly advised by a healthcare provider.
Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression during prolonged use or high-dose therapy.
Patients with diabetes should inform their physician due to potential for elevated blood glucose levels.
Not recommended in children or adolescents under 18 years due to increased risk of systemic absorption.
Use cautiously in patients with liver disease or adrenal gland disorders.
Discontinue if local skin infection develops; concurrent antimicrobial therapy may be necessary.
Avoid use on damaged or infected skin areas unless directed by a physician.
Pregnant and breastfeeding women should use only if clearly needed and under strict medical supervision.
Do not use with other topical or systemic corticosteroids concurrently to avoid additive effects.
Avoid contact with eyes, mucous membranes, and do not ingest.
Wash hands thoroughly after application to prevent unintentional exposure to other body areas.
Inform healthcare providers of all concomitant medications to avoid drug interactions.
Stop using if no clinical improvement is seen within 2 weeks and consult your doctor.

Warnings

Risk of reversible hypothalamic-pituitary-adrenal (HPA) axis suppression causing glucocorticosteroid insufficiency.
Potential development of Cushing’s syndrome, hyperglycemia, and glucosuria with systemic absorption.
Do not use for longer than 2 weeks or exceed recommended dosing limits (50 grams per week).
Avoid use of occlusive dressings as they increase absorption and risk of systemic side effects.
Not recommended for use on face, scalp, axillae, groin, or intertriginous areas.
Children and adolescents under 18 years should not use Impoyz due to higher risk of systemic toxicity.
Pregnancy and breastfeeding safety has not been established; use minimal quantity if prescribed.
If skin infections develop during treatment, discontinue cream and initiate antimicrobial therapy.
Do not use on skin with thin epidermis as it can lead to enhanced absorption and adverse effects.
Avoid concurrent use with other corticosteroid-containing products to prevent additive systemic exposure.
Monitor patients with diabetes for exacerbation of hyperglycemia during treatment.
Excessive use can lead to topical steroid induced skin atrophy and striae formation.
Careful patient selection and adherence to duration limits reduces risk of long-term complications.
Discontinue treatment promptly if signs of corticosteroid adverse effects occur.
Report adverse reactions promptly and seek medical advice if systemic symptoms develop.

Contraindication

Known hypersensitivity or allergy to clobetasol propionate or any components of the cream.
Use in patients with untreated bacterial, fungal, or viral skin infections.
Application on skin areas with thin epidermis such as face, eyelids, and intertriginous folds.
Use in children and adolescents under 18 years of age.
Patients with history of steroid-induced skin reactions or dermatitis.
Patients with systemic candidiasis or other widespread skin infections.
Concurrent use with other corticosteroid products to avoid potentiation.
Pregnant or breastfeeding women unless benefits outweigh risks and under strict medical supervision.
Patients with known adrenal gland disorders unless monitored carefully.
Use in patients with uncontrolled diabetes without close glucose monitoring.
Patients with liver disease without proper medical evaluation.
Do not apply near eyes or mucous membranes to prevent glaucoma and cataracts.
Use is contraindicated in skin conditions where corticosteroids are contraindicated (e.g., rosacea, perioral dermatitis).
History of skin atrophy or fragility increases risk of adverse effects and is a contraindication.
Avoid use in patients with hypersensitivity to penetration enhancers such as Transcutol.

Drug Interactions

Concomitant use with other topical or systemic corticosteroids increases risk of additive effects and systemic toxicity.
No significant interactions expected with oral medications when used topically at recommended doses.
May interact with systemic immunosuppressants increasing risk of immune suppression.
Agents that impair skin barrier function may increase absorption and side effects of Impoyz.
Use with caution alongside drugs affecting glucose metabolism due to potential hyperglycemia.
Potential interaction with drugs inducing or inhibiting cytochrome P450 enzymes affecting systemic clearance if absorbed.
Avoid use with skin irritants or abrasives that may enhance dermal penetration and toxicity.
No direct interactions reported with common over-the-counter medications.
Concurrent use of occlusive dressings increases systemic absorption and risk of interactions.
Topical antimicrobial agents may be used concomitantly if skin infection occurs but monitor for combined effects.
Avoid concurrent use with topical calcineurin inhibitors unless specifically recommended.
Inform healthcare providers of all herbal and vitamin supplements as potential unrecognized interactions may occur.
Discontinue Impoyz before phototherapy to avoid photosensitivity reactions.
No known clinically significant interactions with vaccines.
Patients on systemic corticosteroid therapy should be monitored closely when initiating Impoyz.

Preparations Of The Drug

Impoyz cream contains clobetasol propionate 0.025% (0.25mg per gram of cream).
The cream base includes diethylene glycol monoethyl ether (Transcutol) as a penetration enhancer.
Other inactive ingredients include butylated hydroxytoluene, cetostearyl alcohol, cyclomethicone, glyceryl stearate, PEG 100 stearate, isopropyl myristate, methylparaben, propylparaben, purified water, and white wax.
Supplied in aluminum tubes of 60 grams and 112 grams for topical administration.
Formulated specifically to optimize solubility and skin penetration with reduced steroid concentration compared to standard clobetasol creams.
Non-greasy, easily spreadable cream base designed for adult use on affected skin plaques.
Contains preservatives such as methylparaben and propylparaben to maintain formulation stability.
Manufactured by Primus Pharmaceuticals, Inc.
Storage instructions: Store at room temperature between 20°C to 25°C (68°F to 77°F); do not freeze.
Product designed for dermatological use only; no oral, ocular, or mucous membrane application.
Formulation avoids use of potentially more irritating solubilizers (propylene glycol) in favor of Transcutol to minimize skin barrier disruption.
Packaging ensures protection from contamination and maintains product potency.
FDA approved formulation with approval date December 1, 2017.
Cream consistency suitable for twice daily applications as directed.
Patient counseling should include formulation ingredients to identify potential allergies.